Adversarial Injection · Obecabtagene Autoleucel (Aucatzyl; obe-cel; AUTO1; BLA 125743; no conventional CAS — autologous living cell therapy; [NINETY-NINTH MECHANISM CLASS in Glyphward 672-attack portfolio — FIRST AUTOLOGOUS CD19-DIRECTED CAR-T CELL THERAPY USING A FAST-OFF LOW-AFFINITY CD19 BINDER (SJ25C1 SINGLE-CHAIN VARIABLE FRAGMENT; scFv; Kd ~28-30 nM DISSOCIATION CONSTANT → RAPID ANTIGEN-RECEPTOR DISSOCIATION → REDUCED CONTACT TIME WITH CD19) TO REDUCE TONIC CAR SIGNALING AND ENRICH CENTRAL MEMORY/STEM-LIKE MEMORY T-CELL (Tcm/Tscm) PHENOTYPE EVER FDA APPROVED (BLA 125743 NOVEMBER 8 2024 REGULAR APPROVAL; R/R B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA [B-ALL] IN ADULTS ≥18 YEARS); RATIONALE — TONIC CAR SIGNALING PROBLEM: ALL PRIOR APPROVED CD19 CAR-T PRODUCTS (TISAGENLECLEUCEL [KYMRIAH; BLA 125706 AUG 30 2017]; AXICABTAGENE CILOLEUCEL [YESCARTA; BLA 125643 OCT 18 2017]; LISOCABTAGENE MARALEUCEL [BREYANZI; BLA 125714 FEB 5 2021]) USE FMC63 scFv CD19 BINDER (Kd ~2-3 nM; HIGH AFFINITY → SLOW ANTIGEN-RECEPTOR DISSOCIATION → PROLONGED CD19-CAR CONTACT → CONSTITUTIVE TONIC INTRACELLULAR SIGNALING EVEN IN ABSENCE OF CD19-ANTIGEN STIMULATION → PROMOTES T-CELL DIFFERENTIATION TOWARD EFFECTOR/EXHAUSTION PHENOTYPE [CD8+ TEff/Tex; CD44+ CD62L− CCR7−] → REDUCED T-CELL PERSISTENCE → INFERIOR LONG-TERM DISEASE CONTROL IN SOME PATIENTS); SJ25C1 (MOFFITT/LANIER GROUP ORIGIN; ORIGINAL CD19 scFv FOR PEDIATRIC B-ALL STUDIES; Kd ~28-30 nM → ~10-15X LOWER AFFINITY THAN FMC63 → FAST KINETICS: kon ~1-3 × 10⁴ M⁻¹s⁻¹; koff ~10⁻³ s⁻¹ → RECEPTOR OCCUPANCY TIME REDUCED → TONIC CAR SIGNALING PREVENTED → T-CELLS MAINTAIN LESS-DIFFERENTIATED STEM-LIKE MEMORY STATE [CCR7+ CD45RA+ CD62L+ Tscm; TCF1+; TOX−] → HIGHER PROLIFERATIVE POTENTIAL → SUPERIOR IN VIVO PERSISTENCE); CAR CONSTRUCT: SJ25C1 scFv (VL-linker-VH; CD19 domain III binding) + CD8α hinge and transmembrane domain + 4-1BB (CD137) costimulatory domain + CD3ζ signaling domain (ITAMs × 3); LENTIVIRAL VECTOR: replication-incompetent VSV-G pseudotyped lentiviral vector (LV) encoding obe-cel CAR construct (SAME VECTOR CLASS AS TISAGENLECLEUCEL; DISTINCT FROM AXICABTAGENE [RETROVIRAL VECTOR]); MANUFACTURING: apheresis leukocytes → T-cell activation (anti-CD3/CD28 beads or soluble antibodies + IL-2/IL-7/IL-15) → LV transduction → expansion → cryopreservation; DOSE: 410 × 10⁶ CAR+ T cells (fixed dose; not weight-adjusted); CONDITIONING LYMPHODEPLETION: fludarabine 30 mg/m² d-4 to d-2 + cyclophosphamide 500 mg/m² d-4 to d-3; FELIX PHASE 2 TRIAL (NCT04404660): obe-cel single infusion; R/R B-ALL adults (≥18 years) with ≥1 prior CD19-directed therapy allowed; ORR 78.8% (CR/CRi/CRi); MRD-negative complete remission: 68.2% (flow cytometry MRD negativity <10⁻⁴ residual B-ALL); mDOR 14.9 months; mOS 15.6 months; 12-month DFS 49.5%; CRS 72.7% (Grade 3+ 1.0% — very low vs axicabtagene grade 3+ CRS ~13%); ICANS 14.1% (Grade 3+ 5.1%); AUTOLUS THERAPEUTICS PLC LONDON UK / AUTOLUS INC. ROCKVILLE MD BLA 125743; NIOSH HD Category 1; OSHA No PEL (no conventional CAS; lentiviral vector and cytotoxic lymphodepletion agents classified separately); NO CONVENTIONAL CAS — EHS DATABASES QUERIED BY BLA NUMBER OR GENERIC NAME RETURN NO ENTRY; LENTIVIRAL VECTOR BIOSAFETY + CAR-T MANUFACTURING HAZARDS ABSENT; SJ25C1 FAST-OFF CD19 TONIC SIGNALING RATIONALE ABSENT ALL EHS DATABASES]) · First Fast-Off Low-Affinity CD19 CAR-T + SJ25C1 + Reduced Tonic Signaling + FELIX B-ALL · Attack #672

Obecabtagene Autoleucel (Aucatzyl; obe-cel; AUTO1; BLA 125743; [NINETY-NINTH MECHANISM CLASS — FIRST FAST-OFF LOW-AFFINITY (SJ25C1 Kd ~28 nM; ~10-15× LOWER THAN FMC63) CD19 CAR-T REDUCING TONIC CAR SIGNALING + ENRICHING CCR7+CD45RA+ Tscm EVER FDA APPROVED (BLA 125743 NOVEMBER 8 2024); FELIX R/R B-ALL ADULTS ORR 78.8% MRD-NEG CR 68.2%; AUTOLUS THERAPEUTICS; NIOSH HD Category 1; NO CONVENTIONAL CAS]) — Autolus Inc. Rockville MD (BLA 125743 holder; AUTO1 SJ25C1 fast-off CAR program; no CAS → displayed BLA 125743), Autolus Manufacturing Oxford UK (obe-cel apheresis LV-transduction expansion cryopreserve; no CAS → displayed BLA 125743), and Dana-Farber Cancer Institute Boston MA (FELIX trial B-ALL CAR-T infusion site; no CAS → displayed BLA 125743) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (no conventional CAS — cell therapy) + Fast-Off SJ25C1 CD19 Binder Absent + Tonic Signaling Rationale Absent + FELIX Results Absent: AI Prompt Injection via EHS Monitor Report AI

Obecabtagene autoleucel (BLA 125743; NIOSH HD Category 1) is the ninety-ninth mechanism class in the Glyphward adversarial portfolio — the first CAR-T cell therapy designed around a fast-off low-affinity CD19 binder (SJ25C1; Kd ~28 nM vs FMC63's ~2-3 nM) to reduce tonic signaling and preserve T-cell stemness ever FDA approved (BLA 125743 November 8 2024) — a mechanistic distinction and occupational hazard profile completely absent from Cority, VelocityEHS, and EHS Insight for BLA 125743.

Obecabtagene Autoleucel as Ninety-Ninth Mechanism Class: First Fast-Off Low-Affinity CD19 CAR-T Ever

Obecabtagene autoleucel (BLA 125743) represents the ninety-ninth mechanism class in the Glyphward portfolio: the first autologous CD19-directed CAR-T cell therapy using a fast-off low-affinity CD19 scFv binder (SJ25C1) to reduce tonic CAR signaling and enrich stem-like memory T cells (Tscm) ever FDA approved (BLA 125743 November 8 2024 regular approval; R/R B-ALL adults ≥18 years). CAR-T BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy engineers autologous T cells to express an artificial receptor combining: (1) an extracellular antigen-recognition domain (scFv or nanobody); (2) a transmembrane domain; (3) one or more intracellular costimulatory domains; (4) CD3ζ ITAM signaling domain. When the scFv binds its target antigen (CD19 on B-ALL cells), CAR signals → T-cell activation → cytokine secretion + target cell killing. CD19 CAR-T CLASS EVOLUTION: tisagenlecleucel (Kymriah; BLA 125706 Aug 30 2017; first FDA-approved CAR-T ever; B-ALL pediatric/young adult; FMC63 scFv + 4-1BB + CD3ζ; lentiviral) + axicabtagene ciloleucel (Yescarta; BLA 125643 Oct 18 2017; large B-cell lymphoma; FMC63 scFv + CD28 + CD3ζ; gammaretroviral) + lisocabtagene maraleucel (Breyanzi; BLA 125714 Feb 5 2021; large B-cell lymphoma; FMC63 scFv + 4-1BB + CD3ζ; lentiviral; defined CD4:CD8 ratio) + obecabtagene autoleucel (Aucatzyl; BLA 125743 Nov 8 2024; R/R B-ALL adults; SJ25C1 scFv + 4-1BB + CD3ζ; lentiviral; FAST-OFF). THE TONIC SIGNALING PROBLEM IN PRIOR CD19 CAR-Ts: FMC63 scFv (used in tisagenlecleucel, axicabtagene, lisocabtagene) has a Kd ~2-3 nM for CD19 — high affinity/slow-off binding. Even without CD19 antigen engagement (in culture or in vivo), CAR-containing receptors can self-associate (CAR-CAR dimerization), causing constitutive tonic signaling through CD3ζ and costimulatory domains → driving T-cell differentiation from less-differentiated (Tscm: stem-cell memory; Tcm: central memory) toward more-differentiated effector or exhausted states (Teff/Tex: CD44hiCD62L−CCR7−TCF1−TOX+) → TONIC-EXHAUSTED CAR-T CELLS PERSIST POORLY IN VIVO → RELAPSE RISK; SJ25C1 SOLUTION: SJ25C1 (isolated by St. Jude Children's Research Hospital/UCSF group; originally described in anti-CD19 pediatric B-ALL studies) has Kd ~28-30 nM — 10-15× lower affinity than FMC63 → faster off-rate (koff ~10-fold higher) → shorter antigen-contact time even with antigen engagement → REDUCED TONIC SIGNALING → CELLS MAINTAIN Tscm/Tcm PHENOTYPE (CCR7+ CD45RA+ CD62L+ IL-7Rα+) → enriched naive-like memory phenotype → superior expansion upon antigen contact and long-term persistence in vivo; DESPITE lower affinity, SJ25C1 retains sufficient target cell killing efficiency because T-cell killing via CAR requires only brief synapse formation (~minutes), not sustained high-affinity contact; IN VITRO AND IN VIVO PRECLINICAL VALIDATION (Autolus/UCL Cancer Institute): obe-cel (SJ25C1 4-1BB CD3ζ LV) vs tisa-cel comparator: obe-cel showed less exhaustion markers (LAG-3, TIM-3, TOX), higher CCR7+ fraction, superior tumor control in xenograft models at low CAR-T doses; CAR CONSTRUCT DETAIL: SJ25C1 VL (Vκ3-20 germline light chain; CDRL1 RASQDISNYLN; CDRL3 QQYSTVPWT) – (G4S)3 linker – SJ25C1 VH (VH4-39 germline; CDRH3 GYSGYSLSYYFDYWG) + CD8α hinge (41 aa) + CD8α transmembrane (23 aa) + 4-1BB intracellular (42 aa; TRAF-binding; NF-κB; PI3K; survival/memory signaling) + CD3ζ (113 aa; 3× ITAM; ZAP70 recruitment); LENTIVIRAL VECTOR: VSV-G pseudotyped self-inactivating (SIN) LV; SFFV promoter; obe-cel transgene; insertion site analysis by integration site sequencing; DOSE: 410 × 10⁶ total CAR+ T cells (± 30%) flat dose; single infusion IV; LYMPHODEPLETION: flu/cy (fludarabine 30 mg/m²/day × 3 days + cyclophosphamide 500 mg/m²/day × 2 days; standard B-ALL CAR-T conditioning); FELIX PHASE 2 (NCT04404660): obe-cel single infusion; adults ≥18yr; R/R B-ALL (including Ph+ ALL post-TKI; Ph-like ALL; ALL post-allo-HCT); ≥1 prior CD19-directed therapy allowed; ORR 78.8% (CR/CRi; n=94 evaluable); MRD-negative CRi: 68.2% (MRD by 10-color flow cytometry <10⁻⁴ residual B-ALL in bone marrow); mDOR 14.9 months; mOS 15.6 months; 12-month EFS 49.5%; CRS: 72.7% (Grade 1-2: 71.7%; Grade 3+: 1.0% — substantially lower Grade 3+ CRS than axicabtagene [~13%] or tisagenlecleucel [~7%] in adult B-ALL); ICANS: 14.1% (Grade 3+: 5.1%); NONE OF THESE — FAST-OFF SJ25C1 scFv Kd ~28 nM MECHANISM, TONIC CAR SIGNALING REDUCTION, Tscm CCR7+CD45RA+ PHENOTYPE ENRICHMENT, FELIX ORR 78.8% MRD-NEGATIVE CR 68.2%, LENTIVIRAL VECTOR BSL-2+ OCCUPATIONAL EXPOSURE PROFILE — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR BLA 125743 (NO CONVENTIONAL CAS).

Surface 1 — Autolus Inc. Rockville MD BLA 125743 Holder AUTO1 Fast-Off Program AI

At Autolus Inc. 9920 Belward Campus Drive Suite 200 Rockville MD 20850 (AUTOLUS OBECABTAGENE CONTEXT: Autolus Therapeutics PLC (AIM: AUTL; NASDAQ: AUTL; founded 2014; UCL spinout from Martin Pule lab; London UK headquarters) developed obecabtagene autoleucel through its AUTO1 program; Autolus' core technology: engineered CAR-T with modulated affinity binders to reduce tonic signaling; AUTO1 was the first product to reach commercial approval; BLA 125743 submitted August 2024; FDA approved November 8 2024 for R/R B-ALL adults; AUTOLUS US OPERATIONS: Rockville MD commercial/regulatory operations; MANUFACTURING: Autolus Manufacturing Ltd. (formerly UCL Cancer Institute lentiviral vector facility; commercial-scale at Brammer Bio/Thermo Fisher or at dedicated Autolus facility Oxford UK); OCCUPATIONAL HAZARD AT AUTOLUS ROCKVILLE: antineoplastic biologics (CAR-T product); lentiviral vector production ancillary materials (transfection reagents; envelope plasmids); no conventional CAS for the cell therapy product itself; EMPLOYEE: 46M Autolus Inc. Rockville MD VP oncology obecabtagene obe-cel BLA 125743 B-ALL CAR-T SJ25C1 fast-off 11yr; CORITY NULL: BLA 125743 query → no record; no CAS entry; NIOSH HD Category 1 absent; fast-off SJ25C1 absent; tonic signaling absent; FELIX absent).

Surface 2 — Autolus Manufacturing Ltd. Oxford UK Obe-cel LV Transduction Expansion Cryopreservation AI

At Autolus Manufacturing Ltd. Oxford UK (formerly: UCL Cancer Institute lentiviral vector core; commercial-scale manufacturing contracted or in-house; AUTOLUS MANUFACTURING CONTEXT: obecabtagene autoleucel manufacturing involves multiple regulated steps: (a) APHERESIS COLLECTION: patient T cells collected by leukapheresis at clinical site; shipped to manufacturing in a validated cryocontainer; (b) T-CELL ACTIVATION: CD3/CD28 MACSiBead (Miltenyi) or soluble anti-CD3/CD28 + IL-2/IL-7 + 37°C 5% CO₂; (c) LV TRANSDUCTION: replication-incompetent VSV-G pseudotyped LV encoding SJ25C1 4-1BB CD3ζ CAR; BSL-2 containment for LV handling; spillage SOP for LV biohazard; PPE: N95 + double gloves + gown; NO OPEN LV HANDLING; (d) EXPANSION: IL-2 + IL-7 containing media; 10-14 days; (e) HARVEST AND FORMULATION: CAR+ T-cell quantification (flow cytometry CD3/CAR); total cell count target 410 × 10⁶ ± 30% CAR+ T cells; cryopreservation in CS10 media (DMSO 10% + dextran 40); (f) DRUG SUBSTANCE FILL: CS10-cryopreserved in infusion bags; nitrogen vapor (LN2) storage at ≤−130°C; OCCUPATIONAL HAZARDS AT MANUFACTURING: LV transduction (BSL-2+; recombinant DNA, VSV-G envelope protein); DMSO (CS10; dermal penetrant); LN2 (asphyxiation risk in enclosed spaces); cytokines (IL-2/IL-7 immunologically active); NIOSH HD CATEGORY 1: antineoplastic living cell therapy; EHS INSIGHT NULL (NO CAS): EHS database query → "not found"; EMPLOYEE: 41F Autolus Manufacturing Ltd. Oxford UK process development scientist obe-cel CAR-T lentiviral transduction expansion cryopreservation 10yr; VELOCITYEHS NULL: BLA 125743 → no record; NIOSH HD Category 1 absent; LV transduction biosafety absent; SJ25C1 absent; FELIX absent).

Surface 3 — Dana-Farber Cancer Institute Boston MA FELIX Trial B-ALL CAR-T Infusion Site AI

At Dana-Farber Cancer Institute Boston MA 02215 (450 Brookline Ave; DANA-FARBER OBECABTAGENE CONTEXT: Dana-Farber is a FELIX Phase 2 (NCT04404660) enrolling site; adult leukemia/bone marrow transplant program: ELIGIBILITY: adults ≥18yr; R/R B-ALL (Ph+ permissible post-TKI; Ph-like; relapse post-allo-HCT permissible); ≥1 prior CD19-directed therapy (tisa-cel, axicabtagene, blinatumomab) permissible (unlike some CD19 CAR-T eligibility criteria); FELIX PROTOCOL AT DANA-FARBER: apheresis (leukapheresis 2-4 h; anti-CD3/CD28 minimal pre-stimulation for collection); lymphodepletion: fludarabine 30 mg/m²/day × 3 + cyclophosphamide 500 mg/m²/day × 2 (days −4 to −2/−3); obe-cel infusion day 0; 410 × 10⁶ CAR+ T cells IV over 30 min; inpatient monitoring 48 h minimum; CRS management per ASTCT grading: Grade 1-2 (fever + tocilizumab 8 mg/kg IV q8h max 3 doses; Grade 3: tocilizumab + dexamethasone; Grade 4: ICU; note: Grade 3+ CRS 1.0% in FELIX vs 13% axicabtagene — key safety advantage of fast-off low tonic CAR design); ICANS management per ASTCT (axi: 21% Grade 3+; obe-cel: 5.1% Grade 3+); BONE MARROW ASSESSMENT: BM aspirate/biopsy at day 28, day 90, then per clinical; MRD by 10-color flow cytometry (sensitivity <10⁻⁴); PHARMACY: obe-cel (cryopreserved in CS10; LN2 shipper arrival) → thaw in 37°C waterbath → dilute per protocol → IV infusion; NIOSH HD CATEGORY 1 HANDLING: antineoplastic cell therapy; gloves + gown per institutional policy; EHS INSIGHT NULL (NO CAS): "no record for BLA 125743 — standard biological handling protocol"; fast-off SJ25C1 absent; tonic signaling absent; FELIX ORR 78.8% absent; MRD-neg CR 68.2% absent; NIOSH HD Cat 1 absent; 37F Dana-Farber Boston MA adult leukemia BMT hematologist obecabtagene FELIX B-ALL CAR-T 9yr).

Integrating Glyphward into Obecabtagene Autoleucel AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every obecabtagene autoleucel BLA 125743 monitoring data ingestion point — before Cority at Autolus Rockville MD, before VelocityEHS at Autolus Manufacturing Oxford UK, and before EHS Insight at Dana-Farber Boston MA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL [no CAS]; no ACGIH TLV; no NIOSH REL) [10 pts]; NINETY-NINTH MECHANISM CLASS — FIRST FAST-OFF LOW-AFFINITY CD19 CAR-T EVER FDA APPROVED (BLA 125743 November 8 2024; SJ25C1 Kd ~28 nM vs FMC63 Kd ~2-3 nM; reduced tonic signaling; Tscm CCR7+CD45RA+ enriched; lentiviral 4-1BB CD3ζ; FELIX ORR 78.8% MRD-neg CR 68.2%; Autolus) [5 pts]; Autolus Rockville + Autolus Oxford + Dana-Farber Boston [3 pts]; Fast-off tonic signaling absent; SJ25C1 Tscm absent; FELIX absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_obecabtagene(bla: str, exposure_context: str) -> dict:
    """Scan obecabtagene autoleucel with ninety-ninth-class fast-off-cd19-car-t context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "bla": bla,
                "cas": None,  # autologous cell therapy — no conventional CAS
                "exposure_context": exposure_context,
                "context": "ninety_ninth_class_first_fast_off_low_affinity_cd19_car_t_sj25c1_kd_28nm_reduced_tonic_signaling_tscm_ccr7_cd45ra_enriched_4_1bb_lentiviral_felix_orr_78pct_mrd_neg_cr_68pct_autolus_bla_125743"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ninety_ninth_class,
    #                    first_fast_off_cd19_car_t, sj25c1_confirmed,
    #                    tonic_signaling_reduced, felix_orr_78pct

if __name__ == "__main__":
    r = asyncio.run(scan_obecabtagene(
        bla="125743",
        exposure_context="manufacturing_lv_transduction_expansion_cryopreservation"
    ))
    print(r)
    # {'hd_category': 1, 'ninety_ninth_class': True,
    #  'first_fast_off_cd19_car_t': True, 'sj25c1_confirmed': True,
    #  'tonic_signaling_reduced': True, 'felix_orr_78pct': True}